Develops and manufactures biopharmaceutical products for unmet patient needs in the United States. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 87% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 37.5× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 35% of them.
Analysts' average target sits 47% above today's price.
The stock trades 27% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 87% a year on average.
Sales run at $158.3M a year. A small number, but proof the product has real buyers.
A loss of $68.9M against $158.3M in annual sales.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 35/100.
No clear buy-side message is coming from the executive floor.
On our five-subject report card, LQDA sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: LQDA is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (35/100) says the stock isn’t cheap.